EUVIMEDEUVIMED entdecken
Crossref

Abstract 8533: Association of GLP-1 Receptor Agonists and SGLT2 Inhibitors with Renal Outcomes After Cardiac Surgery

Casey Drubin, Yuxia Ouyang, Natalia Egorova, Matthew Levin

Circulation · 02.11.2026 · 154 (Suppl_1)

DOI: 10.1161/circ.154.suppl_1.8533 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Casey Drubin und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2-i) are increasingly prescribed for patients with type 2 diabetes mellitus (T2DM) undergoing cardiac surgery. Despite established renoprotective benefits in patients with T2DM, the association of preoperative GLP-1 RA and SGLT2-i use with postoperative renal outcomes following cardiac surgery has not been systematically evaluated.

Methods

We conducted a single-center retrospective cohort study of patients with T2DM who underwent elective on-pump cardiac surgery at an urban academic medical center (2020-2025). Patients were classified into four mutually exclusive exposure groups: control, SGLT2-i only, GLP-1 RA only, and dual therapy. Each of the three treatment groups was compared against the control group. Associations were evaluated using generalized overlap propensity score weighting, with IPTW and multivariable regression performed as sensitivity analyses. Acute kidney injury (AKI) was staged per KDIGO criteria. The primary outcome was any-stage AKI; secondary outcomes were severe AKI (Stage 2-3) and postoperative creatinine change.

Results

1,166 cases were included, with medication use as follows: SGLT2-i only 21.7% (n=253), GLP-1 RA only 10.5% (n=122), dual therapy 8.5% (n=99), no medications 59.3% (n=692). Crude AKI rates were similar across groups (Control 30.9%, SGLT2-only 30.4%, GLP-1-only 30.3%, Dual 32.3%). In the primary overlap-weighted analysis, neither SGLT2-i use, GLP-1 RA use, nor dual therapy was associated with differences in the odds of any-stage AKI compared with controls. No significant difference in severe AKI (Stage 2-3) were observed across exposure groups. However, all three treatment groups had smaller postoperative creatinine increases than controls in the primary overlap-weighted analysis (mean difference versus controls — SGLT2-i-only: –0.08 mg/dL, P=0.034; GLP-1-only: –0.09 mg/dL, P=0.020; Dual: –0.08 mg/dL, P=0.035). These findings were consistent in sensitivity analyses.

Conclusions

In this cohort of patients with T2DM undergoing elective on-pump cardiac surgery, neither SGLT2-is nor GLP-1 RAs were associated with increased risk of AKI compared with diabetic controls. However, all treatment groups had smaller increases in postoperative creatinine than controls, suggesting that continuous renal measures may identify perioperative renal effects not captured by binary AKI classifications. These findings support further investigation of the perioperative renal effects of GLP-1 RAs and SGLT2-is in patients with T2DM undergoing cardiac surgery.

Zitieren

APA

Drubin, C., Ouyang, Y., Egorova, N., & Levin, M. (2026). Abstract 8533: Association of GLP-1 Receptor Agonists and SGLT2 Inhibitors with Renal Outcomes After Cardiac Surgery. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.8533

Vancouver

Drubin C, Ouyang Y, Egorova N, Levin M. Abstract 8533: Association of GLP-1 Receptor Agonists and SGLT2 Inhibitors with Renal Outcomes After Cardiac Surgery. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.8533

BibTeX
@article{Drubin2026,
  author = {Drubin, Casey and Ouyang, Yuxia and Egorova, Natalia and Levin, Matthew},
  title = {Abstract 8533: Association of GLP-1 Receptor Agonists and SGLT2 Inhibitors with Renal Outcomes After Cardiac Surgery},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {Suppl_1},
  doi = {10.1161/circ.154.suppl_1.8533}
}
Kostenlos starten →